<?xml version="1.0" encoding="utf-8"?><Regulation lims:pit-date="2022-02-27" hasPreviousVersion="true" lims:lastAmendedDate="2022-02-27" lims:current-date="2025-07-24" lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1338775" lims:id="1338775" gazette-part="II" regulation-type="SOR" xml:lang="en" xmlns:lims="http://justice.gc.ca/lims"><Identification lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1338776" lims:id="1338776"><InstrumentNumber>SOR/2022-18</InstrumentNumber><RegistrationDate><Date><YYYY>2022</YYYY><MM>2</MM><DD>11</DD></Date></RegistrationDate><ConsolidationDate><Date><YYYY>2025</YYYY><MM>7</MM><DD>25</DD></Date></ConsolidationDate><EnablingAuthority lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1338777" lims:id="1338777"><XRefExternal reference-type="act" link="F-27">FOOD AND DRUGS ACT</XRefExternal><XRefExternal reference-type="act" link="P-4">PATENT ACT</XRefExternal></EnablingAuthority><LongTitle lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1338778" lims:id="1338778">Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations</LongTitle><RegulationMakerOrder><RegulationMaker>P.C.</RegulationMaker><OrderNumber>2022-100</OrderNumber><Date><YYYY>2022</YYYY><MM>2</MM><DD>10</DD></Date></RegulationMakerOrder></Identification><Order lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1338779" lims:id="1338779"><Provision lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1338780" lims:id="1338780" format-ref="indent-0-0" language-align="yes"><Text>Her Excellency the Governor General in Council, on the recommendation of the Minister of Health with respect to the provisions of the annexed Regulations other than sections 53 and 54, and on the recommendation of the Minister of Health and the Minister of Industry with respect to those sections 53 and 54, makes the annexed <XRefExternal reference-type="regulation">Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations</XRefExternal> pursuant to</Text><Provision lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1338781" lims:id="1338781" format-ref="indent-1-1"><Label>(a)</Label><Text>section 30<FootnoteRef idref="fn_81200-2-550_hq_30410">a</FootnoteRef> of the <XRefExternal reference-type="act" link="F-27">Food and Drugs Act</XRefExternal><FootnoteRef idref="fn_81200-2-550_hq_30411">b</FootnoteRef>; and</Text><Footnote id="fn_81200-2-550_hq_30410" placement="page" status="official"><Label>a</Label><Text>S.C. 2021, c. 7, s. 9</Text></Footnote><Footnote id="fn_81200-2-550_hq_30411" placement="page" status="official"><Label>b</Label><Text>R.S., c. F-27</Text></Footnote></Provision><Provision lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1338782" lims:id="1338782" format-ref="indent-1-1"><Label>(b)</Label><Text>subsection 134(1)<FootnoteRef idref="fn_81200-2-550_hq_30412">c</FootnoteRef> of the <XRefExternal reference-type="act" link="P-4">Patent Act</XRefExternal><FootnoteRef idref="fn_81200-2-550_hq_30413">d</FootnoteRef>.</Text><Footnote id="fn_81200-2-550_hq_30412" placement="page" status="official"><Label>c</Label><Text>S.C. 2018, c. 27, s. 199</Text></Footnote><Footnote id="fn_81200-2-550_hq_30413" placement="page" status="official"><Label>d</Label><Text>R.S., c. P-4</Text></Footnote></Provision></Provision></Order><Body lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1338783" lims:id="1338783"><Heading lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1338784" lims:id="1338784" level="1"><TitleText>Interpretation</TitleText></Heading><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338785" lims:id="1338785"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338786" lims:id="1338786">Definitions</MarginalNote><Label>1</Label><Text>The following definitions apply in these Regulations.</Text><Definition lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338787" lims:id="1338787"><Text><DefinedTermEn>Act</DefinedTermEn> means the <XRefExternal reference-type="act" link="F-27">Food and Drugs Act</XRefExternal>. (<DefinedTermFr>Loi</DefinedTermFr>)</Text></Definition><Definition lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338788" lims:id="1338788"><Text><DefinedTermEn>COVID-19</DefinedTermEn> means the coronavirus disease 2019. (<DefinedTermFr>COVID-19</DefinedTermFr>)</Text></Definition><Definition lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338789" lims:id="1338789"><Text><DefinedTermEn>COVID-19 drug</DefinedTermEn> means a drug for human use that is manufactured, sold or represented for use in relation to COVID-19. (<DefinedTermFr>drogue utilisée en lien avec la COVID-19</DefinedTermFr>)</Text></Definition><Definition lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338790" lims:id="1338790"><Text><DefinedTermEn>COVID-19 drug authorization</DefinedTermEn> means an authorization to do any of the following activities:</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338791" lims:id="1338791"><Label>(a)</Label><Text>import or sell a COVID-19 drug that is to be tested in a clinical trial;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338792" lims:id="1338792"><Label>(b)</Label><Text>conduct a clinical trial in respect of such a drug. (<DefinedTermFr>autorisation relative à une drogue utilisée en lien avec la COVID-19</DefinedTermFr>)</Text></Paragraph></Definition><Definition lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338793" lims:id="1338793"><Text><DefinedTermEn>COVID-19 medical device</DefinedTermEn> means a medical device that is manufactured, sold or represented for use in relation to COVID-19. (<DefinedTermFr>instrument médical utilisé en lien avec la COVID-19</DefinedTermFr>)</Text></Definition><Definition lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338794" lims:id="1338794"><Text><DefinedTermEn>COVID-19 medical device authorization</DefinedTermEn> means an authorization to do any of the following activities:</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338795" lims:id="1338795"><Label>(a)</Label><Text>import or sell a COVID-19 medical device that is to be tested in a clinical trial;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338796" lims:id="1338796"><Label>(b)</Label><Text>conduct a clinical trial in respect of such a device. (<DefinedTermFr>autorisation relative à un instrument médical utilisé en lien avec la COVID-19</DefinedTermFr>)</Text></Paragraph></Definition><Definition lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338797" lims:id="1338797"><Text><DefinedTermEn>incident</DefinedTermEn> means any incident that involves a COVID-19 medical device tested in a clinical trial and that</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338798" lims:id="1338798"><Label>(a)</Label><Text>is related to a failure of the device or a deterioration in its quality or effectiveness or any inadequacy in its labelling or its directions for use; or</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338799" lims:id="1338799"><Label>(b)</Label><Text>has led to the death or a serious deterioration in the state of health of a clinical trial subject, user or other person or could do so were it to recur. (<DefinedTermFr>incident</DefinedTermFr>)</Text></Paragraph></Definition><Definition lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338800" lims:id="1338800"><Text><DefinedTermEn>qualified investigator</DefinedTermEn> means a person who is a member in good standing of a professional association of persons entitled under the laws of a province to provide health care under their licence in that province and who</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338801" lims:id="1338801"><Label>(a)</Label><Text>conducts a clinical trial; or</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338802" lims:id="1338802"><Label>(b)</Label><Text>in the case of a clinical trial conducted by a team, is the responsible leader of that team. (<DefinedTermFr>chercheur compétent</DefinedTermFr>)</Text></Paragraph></Definition><Definition lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338803" lims:id="1338803"><Text><DefinedTermEn>research ethics board</DefinedTermEn> means a body that is not affiliated with an applicant for a COVID-19 medical device authorization or a COVID-19 drug authorization, or a holder of such an authorization, and whose principal mandate is to approve the initiation of, and conduct periodic reviews of, biomedical research involving human subjects in order to ensure the protection of their rights, safety and well-being. (<DefinedTermFr>comité d’éthique de la recherche</DefinedTermFr>)</Text></Definition></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338804" lims:id="1338804"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338805" lims:id="1338805">Words and expressions</MarginalNote><Label>2</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338806" lims:id="1338806"><Label>(1)</Label><Text>Unless the context requires otherwise, words and expressions used in these Regulations have the same meaning as in the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal> and the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>, as applicable.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338807" lims:id="1338807"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338808" lims:id="1338808">Definition of <DefinitionRef>clinical trial</DefinitionRef></MarginalNote><Label>(2)</Label><Text>However, <DefinedTermEn>clinical trial</DefinedTermEn> has the same meaning as in section 2 of the Act, except as otherwise provided.</Text></Subsection></Section><Heading lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1338809" lims:id="1338809" level="1"><TitleText>Application</TitleText></Heading><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338810" lims:id="1338810"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338811" lims:id="1338811">Application</MarginalNote><Label>3</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338812" lims:id="1338812"><Label>(1)</Label><Text>These Regulations apply to the importation and sale of a COVID-19 medical device, other than a Class I device, that is to be tested in a clinical trial, to the importation and sale of a COVID-19 drug, other than a drug that is described in Schedule C to the Act, that is to be tested in a clinical trial and to the conduct of a clinical trial in respect of such a device or drug.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338813" lims:id="1338813"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338814" lims:id="1338814">Non-application — COVID-19 medical device</MarginalNote><Label>(2)</Label><Text>The <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal>, other than sections 6 and 7 and Schedule 1, do not apply to the importation or sale of a COVID-19 medical device that is to be tested in a clinical trial or to the conduct of a clinical trial in respect of such a device if a COVID-19 medical device authorization has been issued for that device and the authorization has not been revoked in whole.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338815" lims:id="1338815"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338816" lims:id="1338816">Non-application — COVID-19 drug</MarginalNote><Label>(3)</Label><Text>The following regulations do not apply to the importation or sale of a COVID-19 drug that is to be tested in a clinical trial or to the conduct of a clinical trial in respect of such a drug if a COVID-19 drug authorization has been issued for that drug and the authorization has not been revoked in whole:</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338817" lims:id="1338817"><Label>(a)</Label><Text>the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>, other than sections A.01.022 to A.01.024, A.01.026, A.01.041, A.01.042, A.01.050, A.01.067, A.01.068, C.01.015, C.01.036, C.01.037 to C.01.040, C.01.040.2, C.01.051, C.01.064 to C.01.067, C.01.070, C.01.131, C.01.133 to C.01.136 and C.01.435 and Divisions 2 and 4 of Part C; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338818" lims:id="1338818"><Label>(b)</Label><Text>the <XRefExternal reference-type="regulation" link="SOR-2013-178">Blood Regulations</XRefExternal>.</Text></Paragraph></Subsection></Section><Heading lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1338819" lims:id="1338819" level="1"><Label>PART 1</Label><TitleText>COVID-19 Medical Devices</TitleText></Heading><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338820" lims:id="1338820"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338821" lims:id="1338821">Application</MarginalNote><Label>4</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338822" lims:id="1338822"><Label>(1)</Label><Text>An application for a COVID-19 medical device authorization must be submitted to the Minister in the form and manner specified by the Minister.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338823" lims:id="1338823"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338824" lims:id="1338824">Content</MarginalNote><Label>(2)</Label><Text>The application must contain sufficient information and material to enable the Minister to determine whether to issue the authorization and must include the following:</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338825" lims:id="1338825"><Label>(a)</Label><Text>the name and contact information of the applicant and, if applicable, the importer;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338826" lims:id="1338826"><Label>(b)</Label><Text>the name and class of the device;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338827" lims:id="1338827"><Label>(c)</Label><Text>a description of the device and of the materials used in its manufacture and packaging;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338828" lims:id="1338828"><Label>(d)</Label><Text>a description of the features of the device that permit it to be used for the medical conditions, purposes and uses for which it is manufactured, sold or represented, including its performance specifications if those specifications are necessary for proper use;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338829" lims:id="1338829"><Label>(e)</Label><Text>the identifier of the device, including the identifier of any medical device that is part of a system, test kit, medical device group, medical device family or medical device group family;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338830" lims:id="1338830"><Label>(f)</Label><Text>the name and contact information of the manufacturer as they appear on the device label;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338831" lims:id="1338831"><Label>(g)</Label><Text>the address where the device is manufactured, if the address is different from the one provided in the contact information under paragraph (f);</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338832" lims:id="1338832"><Label>(h)</Label><Text>the diagnosis, treatment, mitigation or prevention for which the device is required;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338833" lims:id="1338833"><Label>(i)</Label><Text>a list of the countries other than Canada where the device has been sold, the total number of units sold in those countries and a summary of any reported problems with the device and of any recalls of the device in those countries;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338834" lims:id="1338834"><Label>(j)</Label><Text>the known information in relation to the quality, safety and effectiveness of the device;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338835" lims:id="1338835"><Label>(k)</Label><Text>the directions for use, unless directions are not required for the device to be used safely and effectively;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338836" lims:id="1338836"><Label>(l)</Label><Text>an attestation by the applicant that documented procedures are in place in respect of distribution records, complaint handling, incident reporting and recalls;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338837" lims:id="1338837"><Label>(m)</Label><Text>a copy of the label of the device;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338838" lims:id="1338838"><Label>(n)</Label><Text>the name of the qualified investigator and their qualifications, including their training and experience;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338839" lims:id="1338839"><Label>(o)</Label><Text>the name and contact information of the institution at which the clinical trial is proposed to be conducted;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338840" lims:id="1338840"><Label>(p)</Label><Text>the protocol of the proposed clinical trial, including the number of clinical trial subjects, the number of units of the device proposed to be used for the clinical trial, the hypothesis for and objective of the clinical trial, the period of time during which the clinical trial will be conducted and a copy of the informed consent form;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338841" lims:id="1338841"><Label>(q)</Label><Text>a written undertaking from the qualified investigator to</Text><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338842" lims:id="1338842"><Label>(i)</Label><Text>conduct the clinical trial in accordance with the protocol provided by the applicant,</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338843" lims:id="1338843"><Label>(ii)</Label><Text>inform each clinical trial subject of any risks and benefits associated with the use of the device and obtain the subject’s informed consent for its use, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338844" lims:id="1338844"><Label>(iii)</Label><Text>not permit the device to be used by any other person except under the direction of the qualified investigator; and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338845" lims:id="1338845"><Label>(r)</Label><Text>in the case of a Class III or IV device, for each clinical trial site, the name and contact information of the research ethics board that approved the protocol and informed consent form referred to in paragraph (p), if known at the time of submitting the application.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338846" lims:id="1338846"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338847" lims:id="1338847">Class II devices</MarginalNote><Label>(3)</Label><Text>Despite subsection (2), if the application for the authorization is in respect of a COVID-19 medical device that is a Class II device, the information and material set out in paragraphs (2)(c), (h) to (j), (n) and (q) may be omitted from the application.</Text></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338848" lims:id="1338848"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338849" lims:id="1338849">Issuance</MarginalNote><Label>5</Label><Text>The Minister must issue a COVID-19 medical device authorization if the following requirements are met:</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338850" lims:id="1338850"><Label>(a)</Label><Text>the applicant has submitted to the Minister an application that meets the requirements set out in section <XRefInternal>4</XRefInternal>;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338851" lims:id="1338851"><Label>(b)</Label><Text>the applicant has submitted to the Minister any additional information or material requested under subsection <XRefInternal>10</XRefInternal>(1) in the time, form and manner specified under subsection <XRefInternal>10</XRefInternal>(2); and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338852" lims:id="1338852"><Label>(c)</Label><Text>the Minister determines that</Text><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338853" lims:id="1338853"><Label>(i)</Label><Text>the use of the device that is to be tested in the clinical trial will not unduly affect the health or safety of clinical trial subjects, users or other persons,</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338854" lims:id="1338854"><Label>(ii)</Label><Text>the clinical trial is not contrary to the best interests of clinical trial subjects, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338855" lims:id="1338855"><Label>(iii)</Label><Text>the objectives of the clinical trial are achievable.</Text></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338856" lims:id="1338856"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338857" lims:id="1338857">Research ethics board approval</MarginalNote><Label>6</Label><Text>A holder of a COVID-19 medical device authorization must not import or sell a COVID-19 medical device for which the authorization has been issued or conduct a clinical trial in respect of such a device unless the holder has obtained, for each clinical trial site, the approval of a research ethics board in respect of the protocol and informed consent form referred to in paragraph <XRefInternal>4</XRefInternal>(2)(p).</Text></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338858" lims:id="1338858"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338859" lims:id="1338859">Terms and conditions</MarginalNote><Label>7</Label><Text>The Minister may, at any time, impose terms and conditions on a COVID-19 medical device authorization or amend those terms and conditions.</Text></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338860" lims:id="1338860"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338861" lims:id="1338861">Prohibition</MarginalNote><Label>8</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338862" lims:id="1338862"><Label>(1)</Label><Text>Subject to subsection (2), if the substance of any of the information or material referred to in paragraphs <XRefInternal>4</XRefInternal>(2)(a) to (d), (f), (h), (j), (k) and (p) and, if applicable, submitted under subsection <XRefInternal>10</XRefInternal>(1) is significantly different from the substance of the information or material contained in the application for a COVID-19 medical device authorization,</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338863" lims:id="1338863"><Label>(a)</Label><Text>the conduct of the clinical trial referred to in the authorization that is issued as a result of that application is no longer authorized for the purposes of section 3.1 of the Act; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338864" lims:id="1338864"><Label>(b)</Label><Text>the holder of the authorization must not import or sell the COVID-19 medical device for which the authorization was issued.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338865" lims:id="1338865"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338866" lims:id="1338866">Amendment</MarginalNote><Label>(2)</Label><Text>Subsection (1) does not apply if</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338867" lims:id="1338867"><Label>(a)</Label><Text>the holder of the COVID-19 medical device authorization has submitted to the Minister an application to amend the authorization;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338868" lims:id="1338868"><Label>(b)</Label><Text>the Minister determines that the requirements set out in subparagraphs <XRefInternal>5</XRefInternal>(c)(i) to (iii) are met;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338869" lims:id="1338869"><Label>(c)</Label><Text>the holder has submitted to the Minister any additional information or material requested under subsection <XRefInternal>10</XRefInternal>(1) in the time, form and manner specified under subsection <XRefInternal>10</XRefInternal>(2); and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338870" lims:id="1338870"><Label>(d)</Label><Text>the Minister amends the authorization.</Text></Paragraph></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338871" lims:id="1338871"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338872" lims:id="1338872">Suspension</MarginalNote><Label>9</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338873" lims:id="1338873"><Label>(1)</Label><Text>The Minister may suspend, in whole or in part, a COVID-19 medical device authorization by notice, giving reasons, if</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338874" lims:id="1338874"><Label>(a)</Label><Text>the Minister determines that any of the requirements set out in subparagraphs <XRefInternal>5</XRefInternal>(c)(i) to (iii) is no longer met;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338875" lims:id="1338875"><Label>(b)</Label><Text>the holder of the authorization has not submitted to the Minister any additional information or material requested under subsection <XRefInternal>10</XRefInternal>(1) in the time, form and manner specified under subsection <XRefInternal>10</XRefInternal>(2); or</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338876" lims:id="1338876"><Label>(c)</Label><Text>the holder of the authorization has contravened these Regulations or any provisions of the Act relating to the device.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338877" lims:id="1338877"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338878" lims:id="1338878">Reinstatement</MarginalNote><Label>(2)</Label><Text>The Minister must reinstate a COVID-19 medical device authorization if the holder of the authorization submits to the Minister, in the time, form and manner specified by the Minister, information or material that demonstrates that the situation giving rise to the suspension did not exist or has been corrected.</Text></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338879" lims:id="1338879"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338880" lims:id="1338880">Additional information and material</MarginalNote><Label>10</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338881" lims:id="1338881"><Label>(1)</Label><Text>The Minister may request that an applicant for a COVID-19 medical device authorization or a holder of such an authorization submit any additional information or material, including samples, that is necessary to enable the Minister to determine whether to issue, amend or suspend the authorization.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338882" lims:id="1338882"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338883" lims:id="1338883">Time, form and manner</MarginalNote><Label>(2)</Label><Text>The applicant or holder must submit the information or material in the time, form and manner specified by the Minister.</Text></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338884" lims:id="1338884"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338885" lims:id="1338885">Discontinuance</MarginalNote><Label>11</Label><Text>If a holder of a COVID-19 medical device authorization discontinues, in whole or in part, the clinical trial for which the authorization has been issued, the holder must, without delay,</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338886" lims:id="1338886"><Label>(a)</Label><Text>notify the Minister, in writing, of the discontinuance and the reasons for it;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338887" lims:id="1338887"><Label>(b)</Label><Text>inform all qualified investigators, in writing, of the discontinuance and the reasons for it and advise them, in writing, of any potential risks to the health of clinical trial subjects, users or other persons; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338888" lims:id="1338888"><Label>(c)</Label><Text>in respect of each clinical trial site at which the trial is discontinued, stop the importation or sale of the device as of the date of the discontinuance and take all reasonable measures to ensure the recovery of all unused quantities of the device that have been sold.</Text></Paragraph></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338889" lims:id="1338889"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338890" lims:id="1338890">Discretionary revocation</MarginalNote><Label>12</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338891" lims:id="1338891"><Label>(1)</Label><Text>The Minister may revoke, in whole or in part, a COVID-19 medical device authorization by notice, giving reasons, if the holder of the authorization has not submitted to the Minister, in the time, form and manner specified by the Minister, the information or material referred to in subsection <XRefInternal>9</XRefInternal>(2).</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338892" lims:id="1338892"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338893" lims:id="1338893">Mandatory revocation</MarginalNote><Label>(2)</Label><Text>The Minister must revoke, in whole or in part, the authorization if the Minister has received a notice of discontinuance referred to in paragraph <XRefInternal>11</XRefInternal>(a).</Text></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338894" lims:id="1338894"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338895" lims:id="1338895">Labelling</MarginalNote><Label>13</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338896" lims:id="1338896"><Label>(1)</Label><Text>A person must not import or sell a medical device for which a COVID-19 medical device authorization has been issued or conduct a clinical trial in respect of such a device unless the device has a label that sets out the following information:</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338897" lims:id="1338897"><Label>(a)</Label><Text>the name of the device;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338898" lims:id="1338898"><Label>(b)</Label><Text>the name and contact information of the manufacturer;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338899" lims:id="1338899"><Label>(c)</Label><Text>the identifier of the device, including the identifier of any medical device that is part of a system, test kit, medical device group, medical device family or device group family;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338900" lims:id="1338900"><Label>(d)</Label><Text>in the case of a Class III or IV device, the control number;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338901" lims:id="1338901"><Label>(e)</Label><Text>if the contents are not readily apparent, an indication of what the package contains, expressed in terms appropriate to the device, such as the size, net weight, length, volume or number of units;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338902" lims:id="1338902"><Label>(f)</Label><Text>a statement indicating that the device is sterile, if the device is to be sold in a sterile condition;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338903" lims:id="1338903"><Label>(g)</Label><Text>the expiry date of the device, if applicable;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338904" lims:id="1338904"><Label>(h)</Label><Text>the medical conditions, purposes and uses for which the device is manufactured, sold or represented, including its performance specifications if those specifications are necessary for proper use;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338905" lims:id="1338905"><Label>(i)</Label><Text>the directions for use, unless directions are not required for the device to be used safely and effectively;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338906" lims:id="1338906"><Label>(j)</Label><Text>any special storage conditions applicable to the device;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338907" lims:id="1338907"><Label>(k)</Label><Text>a statement indicating that the device is an investigational device;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338908" lims:id="1338908"><Label>(l)</Label><Text>a statement indicating that the device is to be used by qualified investigators only; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338909" lims:id="1338909"><Label>(m)</Label><Text>in the case of an in vitro diagnostic device, a statement indicating that the performance specifications of the device have not been established.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338910" lims:id="1338910"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338911" lims:id="1338911">Presentation of information</MarginalNote><Label>(2)</Label><Text>The information required by subsection (1) to be set out on the label must be in English and in French.</Text></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338912" lims:id="1338912"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338913" lims:id="1338913">Incident reporting</MarginalNote><Label>14</Label><Text>A holder of a COVID-19 medical device authorization must, within 10 days after becoming aware of an incident inside or outside Canada involving a COVID-19 medical device for which the authorization has been issued, report the incident to the Minister and specify the nature of the incident and the circumstances surrounding it.</Text></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338914" lims:id="1338914"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338915" lims:id="1338915">Records</MarginalNote><Label>15</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338916" lims:id="1338916"><Label>(1)</Label><Text>A holder of a COVID-19 medical device authorization must record, handle and store all information in respect of the clinical trial for which the authorization has been issued in a manner that allows for the complete and accurate reporting as well as the interpretation and verification of the information.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338917" lims:id="1338917"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338918" lims:id="1338918">Content</MarginalNote><Label>(2)</Label><Text>The holder of the authorization must maintain complete and accurate records, which include the information and material referred to in subsection <XRefInternal>4</XRefInternal>(2), in respect of a COVID-19 medical device for which the authorization has been issued in order to establish that the clinical trial is conducted in accordance with these Regulations.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338919" lims:id="1338919"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338920" lims:id="1338920">Retention period</MarginalNote><Label>(3)</Label><Text>The holder of the authorization must retain all records for the period during which the authorization has not been revoked in whole.</Text></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338921" lims:id="1338921"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338922" lims:id="1338922">Distribution records</MarginalNote><Label>16</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338923" lims:id="1338923"><Label>(1)</Label><Text>A holder of a COVID-19 medical device authorization must maintain a distribution record in respect of each device that is imported or sold under the authorization or tested in a clinical trial under the authorization.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338924" lims:id="1338924"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338925" lims:id="1338925">Withdrawal</MarginalNote><Label>(2)</Label><Text>The distribution record must contain sufficient information to permit complete and rapid withdrawal of the COVID-19 medical device for which the authorization has been issued.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338926" lims:id="1338926"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338927" lims:id="1338927">Retention period</MarginalNote><Label>(3)</Label><Text>The holder — or former holder, in the case of an authorization that has been revoked in whole — of the authorization must retain the distribution record for the longer of</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338928" lims:id="1338928"><Label>(a)</Label><Text>the projected useful life of the device, and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338929" lims:id="1338929"><Label>(b)</Label><Text>two years after the date on which the holder took possession, care or control of the device in Canada.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338930" lims:id="1338930"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338931" lims:id="1338931">Timely retrieval</MarginalNote><Label>(4)</Label><Text>Distribution records must be maintained in a manner that will allow their timely retrieval.</Text></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338932" lims:id="1338932"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338933" lims:id="1338933">Complaint handling</MarginalNote><Label>17</Label><Text>A holder of a COVID-19 medical device authorization must, in respect of a COVID-19 medical device for which the authorization has been issued, maintain records of the following:</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338934" lims:id="1338934"><Label>(a)</Label><Text>any reported problems relating to the performance characteristics or safety of the device that are received by the holder after the device was first sold in Canada; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338935" lims:id="1338935"><Label>(b)</Label><Text>all actions taken by the holder in response to those problems.</Text></Paragraph></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338936" lims:id="1338936"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338937" lims:id="1338937">Documented procedures</MarginalNote><Label>18</Label><Text>A holder of a COVID-19 medical device authorization must, in respect of a COVID-19 medical device for which the authorization has been issued, establish and implement documented procedures that will enable the holder to carry out</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338938" lims:id="1338938"><Label>(a)</Label><Text>an effective and timely investigation of the problems referred to in paragraph <XRefInternal>17</XRefInternal>(a); and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338939" lims:id="1338939"><Label>(b)</Label><Text>an effective and timely recall of the device.</Text></Paragraph></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338940" lims:id="1338940"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338941" lims:id="1338941">Information — recall</MarginalNote><Label>19</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338942" lims:id="1338942"><Label>(1)</Label><Text>A holder of a COVID-19 medical device authorization must, on or before recalling a COVID-19 medical device for which the authorization has been issued, provide the Minister with the following:</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338943" lims:id="1338943"><Label>(a)</Label><Text>the name of the device and its identifier, including the identifier of any medical device that is part of a system, test kit, medical device group, medical device family or medical device group family;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338944" lims:id="1338944"><Label>(b)</Label><Text>the name and contact information of the manufacturer and, if applicable, the importer, as well as the name and contact information of the establishment where the device was manufactured, if different from that of the manufacturer;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338945" lims:id="1338945"><Label>(c)</Label><Text>the reason for the recall, the nature of the defectiveness or possible defectiveness and the date on and circumstances under which it was discovered;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338946" lims:id="1338946"><Label>(d)</Label><Text>an evaluation of the risk associated with the defectiveness or possible defectiveness;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338947" lims:id="1338947"><Label>(e)</Label><Text>the number of affected units of the device that were manufactured or sold in Canada or imported into Canada;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338948" lims:id="1338948"><Label>(f)</Label><Text>the period during which the affected units of the device were sold in Canada;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338949" lims:id="1338949"><Label>(g)</Label><Text>the name of each person to whom the affected device was sold and the number of units sold to each person;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338950" lims:id="1338950"><Label>(h)</Label><Text>a copy of any communication issued with respect to the recall;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338951" lims:id="1338951"><Label>(i)</Label><Text>the proposed strategy for conducting the recall, including the date for beginning the recall, information as to how and when the Minister will be informed of the progress of the recall and the proposed date for its completion;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338952" lims:id="1338952"><Label>(j)</Label><Text>the proposed action to prevent a recurrence of the problem; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338953" lims:id="1338953"><Label>(k)</Label><Text>the name, title and telephone number of the representative of the holder of the authorization to contact for any information concerning the recall.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338954" lims:id="1338954"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338955" lims:id="1338955">Information — after completion of recall</MarginalNote><Label>(2)</Label><Text>The holder of the authorization must, as soon as feasible after the completion of the recall, prepare and submit to the Minister a report on</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338956" lims:id="1338956"><Label>(a)</Label><Text>the results of the recall; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338957" lims:id="1338957"><Label>(b)</Label><Text>the action taken to prevent a recurrence of the problem.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338958" lims:id="1338958"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338959" lims:id="1338959">Submission on holder’s behalf</MarginalNote><Label>(3)</Label><Text>Despite subsections (1) and (2), the holder of the authorization may permit the importer of the COVID-19 medical device to prepare and submit, on the holder’s behalf, the information and material required under those subsections if the importer has the same information and material.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338960" lims:id="1338960"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338961" lims:id="1338961">Notice to Minister</MarginalNote><Label>(4)</Label><Text>The holder of the authorization must notify the Minister, in writing, if the holder has permitted the importer to prepare and submit the information and material with respect to the recall on the holder’s behalf.</Text></Subsection></Section><Heading lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1338962" lims:id="1338962" level="1"><Label>PART 2</Label><TitleText>COVID-19 Drugs</TitleText></Heading><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1338963" lims:id="1338963"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338964" lims:id="1338964">Application</MarginalNote><Label>20</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338965" lims:id="1338965"><Label>(1)</Label><Text>An application for a COVID-19 drug authorization must be signed and dated by the applicant’s senior medical or scientific officer in Canada and their senior executive officer and must be submitted to the Minister in the form and manner specified by the Minister.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338966" lims:id="1338966"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338967" lims:id="1338967">Content</MarginalNote><Label>(2)</Label><Text>The application must contain sufficient information and material to enable the Minister to determine whether to issue the authorization and must include the following:</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338968" lims:id="1338968"><Label>(a)</Label><Text>the protocol of the proposed clinical trial;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338969" lims:id="1338969"><Label>(b)</Label><Text>a copy of the statement, as it will be set out in each informed consent form, that states the risks and anticipated benefits arising to the health of clinical trial subjects as a result of their participation in the clinical trial;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338970" lims:id="1338970"><Label>(c)</Label><Text>a clinical trial attestation containing</Text><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338971" lims:id="1338971"><Label>(i)</Label><Text>the title of the protocol and the clinical trial number,</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338972" lims:id="1338972"><Label>(ii)</Label><Text>the brand name, chemical name or code for the drug,</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338973" lims:id="1338973"><Label>(iii)</Label><Text>the therapeutic and pharmacological classifications of the drug,</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338974" lims:id="1338974"><Label>(iv)</Label><Text>the medicinal ingredients of the drug,</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338975" lims:id="1338975"><Label>(v)</Label><Text>the non-medicinal ingredients of the drug,</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338976" lims:id="1338976"><Label>(vi)</Label><Text>the dosage form of the drug,</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338977" lims:id="1338977"><Label>(vii)</Label><Text>the name and contact information of the applicant,</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338978" lims:id="1338978"><Label>(viii)</Label><Text>if the drug is to be imported, the name and contact information of the applicant’s representative in Canada who is responsible for the sale of the drug,</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338979" lims:id="1338979"><Label>(ix)</Label><Text>for each clinical trial site, the name and contact information of the qualified investigator, if known at the time of submitting the application,</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338980" lims:id="1338980"><Label>(x)</Label><Text>for each clinical trial site, the name and contact information of the research ethics board that approved the protocol referred to in paragraph (a) and the informed consent form containing the statement referred to in paragraph (b), if known at the time of submitting the application, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338981" lims:id="1338981"><Label>(xi)</Label><Text>a statement that</Text><Clause lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338982" lims:id="1338982"><Label>(A)</Label><Text>the clinical trial will be conducted in accordance with good clinical practices and these Regulations, and</Text></Clause><Clause lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338983" lims:id="1338983"><Label>(B)</Label><Text>all information and material contained in, or referenced by, the application is complete and accurate and is not false or misleading;</Text></Clause></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338984" lims:id="1338984"><Label>(d)</Label><Text>the name and contact information of any research ethics board that has previously refused to approve the protocol referred to in paragraph (a), its reasons for doing so and the date on which the refusal was given, if known at the time of submitting the application;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338985" lims:id="1338985"><Label>(e)</Label><Text>the physical, chemical and pharmaceutical properties of the drug;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338986" lims:id="1338986"><Label>(f)</Label><Text>the pharmacological aspects of the drug, including its metabolites in all animal species tested;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338987" lims:id="1338987"><Label>(g)</Label><Text>the pharmacokinetics of the drug and the drug metabolism, including the biological transformation of the drug in all animal species tested;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338988" lims:id="1338988"><Label>(h)</Label><Text>any toxicological effects of the drug in any animal species tested under a single dose study, a repeated dose study or a special study;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338989" lims:id="1338989"><Label>(i)</Label><Text>any results of carcinogenicity studies in any animal species tested in respect of the drug;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338990" lims:id="1338990"><Label>(j)</Label><Text>any results of clinical pharmacokinetic studies of the drug;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338991" lims:id="1338991"><Label>(k)</Label><Text>any of the following information that was obtained from previous clinical trials in humans in respect of the drug;</Text><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338992" lims:id="1338992"><Label>(i)</Label><Text>safety,</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338993" lims:id="1338993"><Label>(ii)</Label><Text>pharmacodynamics,</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338994" lims:id="1338994"><Label>(iii)</Label><Text>efficacy, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338995" lims:id="1338995"><Label>(iv)</Label><Text>dose responses;</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338996" lims:id="1338996"><Label>(l)</Label><Text>if the drug contains a human-sourced excipient, including any used in the placebo,</Text><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338997" lims:id="1338997"><Label>(i)</Label><Text>in the case where the excipient has been assigned a drug identification number under subsection C.01.014.2(1) of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal> or, in the case of a new drug, has been issued a notice of compliance under subsection C.08.004(1) of those Regulations, a statement to that effect, or</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338998" lims:id="1338998"><Label>(ii)</Label><Text>in any other case, sufficient information to support the identity, purity, potency, stability and safety of the excipient;</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1338999" lims:id="1338999"><Label>(m)</Label><Text>if the drug has not been assigned a drug identification number under subsection C.01.014.2(1) of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal> or, in the case of a new drug, a notice of compliance has not been issued under section C.08.004 or C.08.004.01 of those Regulations, the chemistry and manufacturing information in respect of the drug, including its site of manufacture; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339000" lims:id="1339000"><Label>(n)</Label><Text>the proposed date for the commencement of the clinical trial at each clinical trial site, if known at the time of submitting the application.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339001" lims:id="1339001"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339002" lims:id="1339002">Marketed drug</MarginalNote><Label>(3)</Label><Text>If the application for the authorization is in respect of a COVID-19 drug that meets the requirements of paragraphs <XRefInternal>27</XRefInternal>(a) to (c), the application must also contain</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339003" lims:id="1339003"><Label>(a)</Label><Text>a copy of the label of the drug; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339004" lims:id="1339004"><Label>(b)</Label><Text>information demonstrating that the proposed use of the drug is consistent with the standard of medical practice.</Text></Paragraph></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339005" lims:id="1339005"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339006" lims:id="1339006">Issuance</MarginalNote><Label>21</Label><Text>The Minister must issue a COVID-19 drug authorization if the following requirements are met:</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339007" lims:id="1339007"><Label>(a)</Label><Text>the applicant has submitted to the Minister an application that meets the requirements set out in section <XRefInternal>20</XRefInternal>;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339008" lims:id="1339008"><Label>(b)</Label><Text>the applicant has submitted to the Minister any additional information or material requested under subsection <XRefInternal>30</XRefInternal>(1) in the time, form and manner specified under subsection <XRefInternal>30</XRefInternal>(2); and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339009" lims:id="1339009"><Label>(c)</Label><Text>the Minister determines that</Text><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339010" lims:id="1339010"><Label>(i)</Label><Text>the use of the drug that is to be tested in the clinical trial will not unduly affect the health or safety of clinical trial subjects or other persons,</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339011" lims:id="1339011"><Label>(ii)</Label><Text>the clinical trial is not contrary to the best interests of clinical trial subjects, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339012" lims:id="1339012"><Label>(iii)</Label><Text>the objectives of the clinical trial are achievable.</Text></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339013" lims:id="1339013"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339014" lims:id="1339014">Additional information prior to clinical trial</MarginalNote><Label>22</Label><Text>A holder of a COVID-19 drug authorization must not import or sell a COVID-19 drug for which the authorization has been issued or conduct a clinical trial in respect of such a drug unless the holder has</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339015" lims:id="1339015"><Label>(a)</Label><Text>for each clinical trial site, obtained the approval of a research ethics board in respect of the protocol referred to in paragraph <XRefInternal>20</XRefInternal>(2)(a) and the informed consent form that contains the statement referred to in paragraph <XRefInternal>20</XRefInternal>(2)(b); and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339016" lims:id="1339016"><Label>(b)</Label><Text>submitted to the Minister the information and material referred to in subparagraphs <XRefInternal>20</XRefInternal>(2)(c)(ix) and (x) and paragraphs <XRefInternal>20</XRefInternal>(2)(d) and (n), if it was not submitted at the time of submitting the application.</Text></Paragraph></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339017" lims:id="1339017"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339018" lims:id="1339018">Terms and conditions</MarginalNote><Label>23</Label><Text>The Minister may, at any time, impose terms and conditions on a COVID-19 drug authorization or amend those terms and conditions.</Text></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339019" lims:id="1339019"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339020" lims:id="1339020">Prohibition</MarginalNote><Label>24</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339021" lims:id="1339021"><Label>(1)</Label><Text>Subject to subsection (2), if the substance of any of the information or material referred to in paragraph <XRefInternal>20</XRefInternal>(2)(a) or (m) is significantly different from the substance of the information or material contained in the application for a COVID-19 drug authorization,</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339022" lims:id="1339022"><Label>(a)</Label><Text>the conduct of the clinical trial referred to in the authorization that is issued as a result of that application is no longer authorized for the purposes of section 3.1 of the Act; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339023" lims:id="1339023"><Label>(b)</Label><Text>the holder of the authorization must not import or sell the COVID-19 drug for which the authorization was issued.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339024" lims:id="1339024"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339025" lims:id="1339025">Amendment</MarginalNote><Label>(2)</Label><Text>Subsection (1) does not apply if</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339026" lims:id="1339026"><Label>(a)</Label><Text>the holder of the COVID-19 drug authorization has submitted to the Minister an application to amend the authorization;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339027" lims:id="1339027"><Label>(b)</Label><Text>for each clinical trial site, the holder has obtained the approval of a research ethics board in respect of the protocol referred to in paragraph <XRefInternal>20</XRefInternal>(2)(a) and the informed consent form that contains the statement referred to in paragraph <XRefInternal>20</XRefInternal>(2)(b);</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339028" lims:id="1339028"><Label>(c)</Label><Text>the holder has submitted to the Minister the information and material referred to in subparagraphs <XRefInternal>20</XRefInternal>(2)(c)(ix) and (x) and paragraphs <XRefInternal>20</XRefInternal>(2)(d) and (n), if it was not submitted at the time of submitting the application;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339029" lims:id="1339029"><Label>(d)</Label><Text>the Minister determines that the requirements set out in subparagraphs <XRefInternal>21</XRefInternal>(c)(i) to (iii) are met;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339030" lims:id="1339030"><Label>(e)</Label><Text>the holder has submitted to the Minister any additional information or material requested under subsection <XRefInternal>30</XRefInternal>(1) in the time, form and manner specified under subsection <XRefInternal>30</XRefInternal>(2); and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339031" lims:id="1339031"><Label>(f)</Label><Text>the Minister amends the authorization.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339032" lims:id="1339032"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339033" lims:id="1339033">Immediate change</MarginalNote><Label>(3)</Label><Text>Despite subsections (1) and (2), if an immediate change is required to be made to the substance of any of the information or material referred to in paragraph <XRefInternal>20</XRefInternal>(2)(a) or (m) because the clinical trial or the use of the COVID-19 drug that is tested in the clinical trial endangers the health of a clinical trial subject or other person, the holder of the authorization may immediately make the change.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339034" lims:id="1339034"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339035" lims:id="1339035">Immediate change — application to amend</MarginalNote><Label>(4)</Label><Text>The holder of the authorization must, within 15 days after making the change referred to in subsection (3), submit the application referred to in subsection (2) to amend the authorization.</Text></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339036" lims:id="1339036"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339037" lims:id="1339037">Prohibition — import</MarginalNote><Label>25</Label><Text>A holder of a COVID-19 drug authorization must not import a COVID-19 drug for which the authorization has been issued if the sale of the drug would constitute a violation of the Act.</Text></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339038" lims:id="1339038"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339039" lims:id="1339039">Prohibition — import and sale</MarginalNote><Label>26</Label><Text>A holder of a COVID-19 drug authorization must not import or sell a COVID-19 drug for which the authorization has been issued unless the holder has a representative in Canada who is responsible for the sale of the drug.</Text></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339040" lims:id="1339040"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339041" lims:id="1339041">Marketed drugs</MarginalNote><Label>27</Label><Text>Paragraphs <XRefInternal>20</XRefInternal>(2)(e) to (l), section <XRefInternal>33</XRefInternal> and paragraphs <XRefInternal>35</XRefInternal>(2)(a) to (c) do not apply to a COVID-19 drug for which a COVID-19 drug authorization has been issued if</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339042" lims:id="1339042"><Label>(a)</Label><Text>the use of the drug is consistent with the standard of medical practice;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339043" lims:id="1339043"><Label>(b)</Label><Text>the drug has been issued a notice of compliance under subsection C.08.004(1) of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal> or has been assigned a drug identification number under subsection C.01.014.2(1) of those Regulations; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339044" lims:id="1339044"><Label>(c)</Label><Text>the clinical trial for which the authorization has been issued is in respect of a purpose or condition of use other than that for which the notice of compliance was issued or drug identification number was assigned.</Text></Paragraph></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339045" lims:id="1339045"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339046" lims:id="1339046">Good clinical practices</MarginalNote><Label>28</Label><Text>A holder of a COVID-19 drug authorization must ensure that the clinical trial for which the authorization has been issued is conducted in accordance with good clinical practices and, without limiting the generality of the foregoing, must ensure that</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339047" lims:id="1339047"><Label>(a)</Label><Text>the clinical trial is scientifically sound and clearly described in the protocol;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339048" lims:id="1339048"><Label>(b)</Label><Text>the clinical trial is conducted, and the drug is used, in accordance with the protocol and these Regulations;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339049" lims:id="1339049"><Label>(c)</Label><Text>systems and procedures that assure the quality of every aspect of the clinical trial are implemented;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339050" lims:id="1339050"><Label>(d)</Label><Text>for each clinical trial site, the approval of a research ethics board is obtained before the clinical trial begins;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339051" lims:id="1339051"><Label>(e)</Label><Text>at each clinical trial site, there is no more than one qualified investigator;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339052" lims:id="1339052"><Label>(f)</Label><Text>at each clinical trial site, medical care and medical decisions, in respect of the clinical trial, are under the supervision of a health care professional who is authorized to provide medical care and make medical decisions;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339053" lims:id="1339053"><Label>(g)</Label><Text>each person who is involved in the conduct of the clinical trial is qualified by education, training and experience to perform their respective tasks;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339054" lims:id="1339054"><Label>(h)</Label><Text>informed consent, given in accordance with the applicable laws governing consent, is obtained from every person before they participate in the clinical trial, but only after that person has been informed of</Text><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339055" lims:id="1339055"><Label>(i)</Label><Text>the risks and anticipated benefits to their health arising from participation in the clinical trial, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339056" lims:id="1339056"><Label>(ii)</Label><Text>all other aspects of the clinical trial that are necessary for that person to make the decision to participate in the clinical trial; and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339057" lims:id="1339057"><Label>(i)</Label><Text>the drug is manufactured, handled and stored in accordance with the applicable good manufacturing practices referred to in Divisions 2 and 4 of Part C of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>, with the exception of sections C.02.019, C.02.025 and C.02.026 of those Regulations.</Text></Paragraph></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339058" lims:id="1339058"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339059" lims:id="1339059">Suspension</MarginalNote><Label>29</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339060" lims:id="1339060"><Label>(1)</Label><Text>The Minister may suspend, in whole or in part, a COVID-19 drug authorization by notice, giving reasons, if</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339061" lims:id="1339061"><Label>(a)</Label><Text>the Minister determines that any of the requirements set out in subparagraphs <XRefInternal>21</XRefInternal>(c)(i) to (iii) is no longer met;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339062" lims:id="1339062"><Label>(b)</Label><Text>the holder of the authorization has not submitted to the Minister any additional information or material requested under subsection <XRefInternal>30</XRefInternal>(1) in the time, form and manner specified under subsection <XRefInternal>30</XRefInternal>(2); or</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339063" lims:id="1339063"><Label>(c)</Label><Text>the holder of the authorization has contravened these Regulations or any provisions of the Act relating to the drug.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339064" lims:id="1339064"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339065" lims:id="1339065">Reinstatement</MarginalNote><Label>(2)</Label><Text>The Minister must reinstate a COVID-19 drug authorization if the holder of the authorization submits to the Minister, in the time, form and manner specified by the Minister, information or material that demonstrates that the situation giving rise to the suspension did not exist or has been corrected.</Text></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339066" lims:id="1339066"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339067" lims:id="1339067">Additional information and material</MarginalNote><Label>30</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339068" lims:id="1339068"><Label>(1)</Label><Text>The Minister may request that an applicant for a COVID-19 drug authorization or a holder of such an authorization submit any additional information or material, including samples, that is necessary to enable the Minister to determine whether to issue, amend or suspend the authorization.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339069" lims:id="1339069"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339070" lims:id="1339070">Time, form and manner</MarginalNote><Label>(2)</Label><Text>The applicant or holder must submit the information or material in the time, form and manner specified by the Minister.</Text></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339071" lims:id="1339071"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339072" lims:id="1339072">Discontinuance</MarginalNote><Label>31</Label><Text>If a holder of a COVID-19 drug authorization discontinues, in whole or in part, the clinical trial for which the authorization has been issued, the holder must, without delay,</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339073" lims:id="1339073"><Label>(a)</Label><Text>notify the Minister, in writing, of the discontinuance and the reasons for it;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339074" lims:id="1339074"><Label>(b)</Label><Text>inform all qualified investigators, in writing, of the discontinuance and the reasons for it and advise them, in writing, of any potential risks to the health of clinical trial subjects or other persons; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339075" lims:id="1339075"><Label>(c)</Label><Text>in respect of each clinical trial site at which the trial is discontinued, stop the importation or sale of the drug as of the date of the discontinuance and take all reasonable measures to ensure the recovery of all unused quantities of the drug that have been sold.</Text></Paragraph></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339076" lims:id="1339076"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339077" lims:id="1339077">Discretionary revocation</MarginalNote><Label>32</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339078" lims:id="1339078"><Label>(1)</Label><Text>The Minister may revoke, in whole or in part, a COVID-19 drug authorization by notice, giving reasons, if the holder of the authorization has not submitted to the Minister, in the time, form and manner specified by the Minister, the information or material referred to in subsection <XRefInternal>29</XRefInternal>(2).</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339079" lims:id="1339079"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339080" lims:id="1339080">Mandatory revocation</MarginalNote><Label>(2)</Label><Text>The Minister must revoke, in whole or in part, the authorization if the Minister has received a notice of discontinuance referred to in paragraph <XRefInternal>31</XRefInternal>(a).</Text></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339081" lims:id="1339081"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339082" lims:id="1339082">Labelling</MarginalNote><Label>33</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339083" lims:id="1339083"><Label>(1)</Label><Text>A person must not import or sell a COVID-19 drug for which a COVID-19 drug authorization has been issued or conduct a clinical trial in respect of such a drug unless the drug has a label that sets out the following information:</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339084" lims:id="1339084"><Label>(a)</Label><Text>a statement indicating that the drug is an investigational drug to be used only by a qualified investigator;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339085" lims:id="1339085"><Label>(b)</Label><Text>the name, number or identifying mark of the drug;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339086" lims:id="1339086"><Label>(c)</Label><Text>the expiration date of the drug;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339087" lims:id="1339087"><Label>(d)</Label><Text>the recommended storage conditions for the drug;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339088" lims:id="1339088"><Label>(e)</Label><Text>the lot number of the drug;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339089" lims:id="1339089"><Label>(f)</Label><Text>the name and contact information of the holder of the authorization; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339090" lims:id="1339090"><Label>(g)</Label><Text>the protocol code or identification.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339091" lims:id="1339091"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339092" lims:id="1339092">Presentation of information</MarginalNote><Label>(2)</Label><Text>The information required by subsection (1) to be set out on the label must be in English and in French.</Text></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339093" lims:id="1339093"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339094" lims:id="1339094">Serious unexpected adverse drug reaction</MarginalNote><Label>34</Label><Text>A holder of a COVID-19 drug authorization must inform the Minister of any serious unexpected adverse drug reaction that has occurred inside or outside Canada, in respect of the COVID-19 drug that is tested in the clinical trial, as follows:</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339095" lims:id="1339095"><Label>(a)</Label><Text>within 15 days after becoming aware of the reaction, if it is neither fatal nor life‑threatening; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339096" lims:id="1339096"><Label>(b)</Label><Text>within seven days after becoming aware of the reaction, if it is fatal or life‑threatening.</Text></Paragraph></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339097" lims:id="1339097"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339098" lims:id="1339098">Records</MarginalNote><Label>35</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339099" lims:id="1339099"><Label>(1)</Label><Text>A holder of a COVID-19 drug authorization must record, handle and store all information in respect of the clinical trial for which the authorization has been issued in a manner that allows for the complete and accurate reporting as well as the interpretation and verification of the information.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339100" lims:id="1339100"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339101" lims:id="1339101">Content</MarginalNote><Label>(2)</Label><Text>The holder of the authorization must maintain complete and accurate records, which include the following, in respect of a COVID-19 drug for which the authorization has been issued in order to establish that the clinical trial is conducted in accordance with good clinical practices and these Regulations:</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339102" lims:id="1339102"><Label>(a)</Label><Text>the information and material referred to in paragraphs <XRefInternal>20</XRefInternal>(2)(e) to (k);</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339103" lims:id="1339103"><Label>(b)</Label><Text>records respecting each change made to the information and material referred to in paragraph (a), the rationale for each change and documentation that supports each change;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339104" lims:id="1339104"><Label>(c)</Label><Text>records respecting all adverse events in respect of the drug that have occurred inside or outside Canada, including the indication for use and the dosage form of the drug at the time of the adverse event;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339105" lims:id="1339105"><Label>(d)</Label><Text>in respect of a drug that meets the requirements of paragraphs <XRefInternal>27</XRefInternal>(a) to (c), records respecting any serious unexpected adverse drug reaction that has occurred inside or outside Canada;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339106" lims:id="1339106"><Label>(e)</Label><Text>records respecting the enrolment of clinical trial subjects, including information that allows all subjects to be identified and contacted in the event that the sale of the drug may endanger the health of the subjects or other persons;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339107" lims:id="1339107"><Label>(f)</Label><Text>records respecting the shipment, receipt, disposition, return and destruction of the drug;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339108" lims:id="1339108"><Label>(g)</Label><Text>for each clinical trial site, an undertaking, signed and dated by the qualified investigator prior to the commencement of their responsibilities in respect of the clinical trial stating that</Text><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339109" lims:id="1339109"><Label>(i)</Label><Text>the qualified investigator will conduct the clinical trial in accordance with good clinical practices, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339110" lims:id="1339110"><Label>(ii)</Label><Text>the qualified investigator will immediately, on discontinuance of the clinical trial, in whole or in part, by the holder, inform both the clinical trial subjects and the research ethics board of the discontinuance, provide them with the reasons for the discontinuance and advise them, in writing, of any potential risks to the health of subjects or other persons;</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339111" lims:id="1339111"><Label>(h)</Label><Text>for each clinical trial site, a copy of the protocol, informed consent form and any amendment to the protocol or informed consent form that have been approved by a research ethics board for that site; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339112" lims:id="1339112"><Label>(i)</Label><Text>for each clinical trial site, an attestation, signed and dated by a research ethics board, stating that it has reviewed and approved the protocol and informed consent form and that the board carries out its functions in a manner consistent with good clinical practices.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339113" lims:id="1339113"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339114" lims:id="1339114">Retention period</MarginalNote><Label>(3)</Label><Text>The holder — or former holder, in the case of an authorization that has been revoked in whole — of the authorization must retain all records referred to in subsection (2) for a period of 15 years.</Text></Subsection></Section><Heading lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1339115" lims:id="1339115" level="1"><Label>PART 3</Label><TitleText>General</TitleText></Heading><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339116" lims:id="1339116"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339117" lims:id="1339117">Remote written informed consent</MarginalNote><Label>36</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339118" lims:id="1339118"><Label>(1)</Label><Text>If a qualified investigator is not able to obtain, in person, the written informed consent of a person to participate in a clinical trial in respect of a COVID-19 medical device for which a COVID-19 medical device authorization has been issued or a COVID-19 drug for which a COVID-19 drug authorization has been issued, the qualified investigator may obtain the written informed consent remotely.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339119" lims:id="1339119"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339120" lims:id="1339120">Non-written informed consent</MarginalNote><Label>(2)</Label><Text>In the case where the person is not able to provide their written informed consent, the qualified investigator may obtain their non-written informed consent if the following conditions are met:</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339121" lims:id="1339121"><Label>(a)</Label><Text>the qualified investigator reads the contents of the informed consent form to the person;</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339122" lims:id="1339122"><Label>(b)</Label><Text>the person provides their informed consent before a witness; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339123" lims:id="1339123"><Label>(c)</Label><Text>an attestation by the witness that the person has provided their informed consent is provided to the qualified investigator as soon as feasible.</Text></Paragraph></Subsection></Section><Heading lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1339124" lims:id="1339124" level="1"><Label>PART 4</Label><TitleText>Other Clinical Trials</TitleText></Heading><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339125" lims:id="1339125"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339126" lims:id="1339126">Exemption — certain drugs</MarginalNote><Label>37</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339127" lims:id="1339127"><Label>(1)</Label><Text>A person that is authorized under Division 5 of Part C of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal> to sell or import a drug for the purposes of a clinical trial — and any other person that conducts the clinical trial — is, in respect of the clinical trial, exempt from section 3.1 of the Act.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339128" lims:id="1339128"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339129" lims:id="1339129">Clarification — suspension and cancellation</MarginalNote><Label>(2)</Label><Text>For greater certainty, the exemption does not apply</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339130" lims:id="1339130"><Label>(a)</Label><Text>if the authorization to sell or import the drug is suspended in its entirety; or</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339131" lims:id="1339131"><Label>(b)</Label><Text>in respect of the conduct of the clinical trial at a clinical trial site, if the authorization to sell or import the drug is suspended or cancelled in respect of that site.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339132" lims:id="1339132"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339133" lims:id="1339133">Definition of <DefinitionRef>clinical trial</DefinitionRef></MarginalNote><Label>(3)</Label><Text>In this section, <DefinedTermEn>clinical trial</DefinedTermEn> has the same meaning as in section C.05.001 of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>.</Text></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339134" lims:id="1339134"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339135" lims:id="1339135">Exemption — positron-emitting radiopharmaceuticals</MarginalNote><Label>38</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339136" lims:id="1339136"><Label>(1)</Label><Text>A person that is authorized under Division 3 of Part C of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal> to sell or import a positron-emitting radiopharmaceutical for the purposes of a study — and any other person that conducts the study — is, in respect of the study, exempt from section 3.1 of the Act.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339137" lims:id="1339137"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339138" lims:id="1339138">Clarification — suspension and cancellation</MarginalNote><Label>(2)</Label><Text>For greater certainty, the exemption does not apply</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339139" lims:id="1339139"><Label>(a)</Label><Text>if the authorization to sell or import the radiopharmaceutical is suspended in its entirety; or</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339140" lims:id="1339140"><Label>(b)</Label><Text>in respect of the conduct of the study at a study site, if the authorization to sell or import the radiopharmaceutical is suspended or cancelled in respect of that site.</Text></Paragraph></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339141" lims:id="1339141"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339142" lims:id="1339142">Exemption — natural health products</MarginalNote><Label>39</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339143" lims:id="1339143"><Label>(1)</Label><Text>A person that is authorized under Part 4 of the <XRefExternal reference-type="regulation" link="SOR-2003-196">Natural Health Products Regulations</XRefExternal> to sell or import a natural health product for the purposes of a clinical trial — and any other person that conducts the clinical trial — is, in respect of the clinical trial, exempt from section 3.1 of the Act.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339144" lims:id="1339144"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339145" lims:id="1339145">Clarification — suspension and cancellation</MarginalNote><Label>(2)</Label><Text>For greater certainty, the exemption does not apply</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339146" lims:id="1339146"><Label>(a)</Label><Text>if the authorization to sell or import the natural health product is suspended in its entirety; or</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339147" lims:id="1339147"><Label>(b)</Label><Text>in respect of the conduct of the clinical trial at a clinical trial site, if the authorization to sell or import the natural health product is suspended or cancelled in respect of that site.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339148" lims:id="1339148"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339149" lims:id="1339149">Definitions</MarginalNote><Label>(3)</Label><Text>The following definitions apply in this section.</Text><Definition lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339150" lims:id="1339150"><Text><DefinedTermEn>clinical trial</DefinedTermEn> has the same meaning as in section 63 of the <XRefExternal reference-type="regulation" link="SOR-2003-196">Natural Health Products Regulations</XRefExternal>. (<DefinedTermFr>essai clinique</DefinedTermFr>)</Text></Definition><Definition lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339151" lims:id="1339151"><Text><DefinedTermEn>natural health product</DefinedTermEn> has the same meaning as in subsection 1(1) of the <XRefExternal reference-type="regulation" link="SOR-2003-196">Natural Health Products Regulations</XRefExternal>. (<DefinedTermFr>produit de santé naturel</DefinedTermFr>)</Text></Definition></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339152" lims:id="1339152"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339153" lims:id="1339153">Exemption — medical devices</MarginalNote><Label>40</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339154" lims:id="1339154"><Label>(1)</Label><Text>A person that is authorized under Part 3 of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal> to sell a medical device for investigational testing — and any person that conducts the testing of the device — is, in respect of the testing, exempt from section 3.1 of the Act.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339155" lims:id="1339155"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339156" lims:id="1339156">Exception</MarginalNote><Label>(2)</Label><Text>The exemption does not apply in respect of any person to whom the medical device can no longer be sold as a result of a measure taken by the Minister under subsection 85(2) of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal>.</Text></Subsection></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339157" lims:id="1339157"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339158" lims:id="1339158">Suspension — deemed holder</MarginalNote><Label>41</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339159" lims:id="1339159"><Label>(1)</Label><Text>An authorization to conduct a clinical trial in respect of a drug is suspended if</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339160" lims:id="1339160"><Label>(a)</Label><Text>the holder is deemed to hold the authorization under any of sections 180 to 182 of the <XRefExternal reference-type="act" link="B-9.8593">Budget Implementation Act, 2019, No. 1</XRefExternal>; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339161" lims:id="1339161"><Label>(b)</Label><Text>the holder’s authorization to sell or import the drug for the purposes of the clinical trial is suspended under</Text><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339162" lims:id="1339162"><Label>(i)</Label><Text>section C.03.317, C.05.016 or C.05.017 of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>, or</Text></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339163" lims:id="1339163"><Label>(ii)</Label><Text>section 80 or 81 of the <XRefExternal reference-type="regulation" link="SOR-2003-196">Natural Health Products Regulations</XRefExternal>.</Text></Subparagraph></Paragraph></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339164" lims:id="1339164"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339165" lims:id="1339165">Reinstatement</MarginalNote><Label>(2)</Label><Text>An authorization that is suspended under subsection (1) is reinstated if the authorization referred to in paragraph (1)(b) is reinstated.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339166" lims:id="1339166"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339167" lims:id="1339167">Revocation — deemed holder</MarginalNote><Label>(3)</Label><Text>An authorization to conduct a clinical trial in respect of a drug or medical device is revoked if</Text><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339168" lims:id="1339168"><Label>(a)</Label><Text>the holder is deemed to hold the authorization under any of sections 180 to 183 of the <XRefExternal reference-type="act" link="B-9.8593">Budget Implementation Act, 2019, No. 1</XRefExternal>; and</Text></Paragraph><Paragraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339169" lims:id="1339169"><Label>(b)</Label><Text>the holder’s authorization to sell or import the drug or device for the purposes of the clinical trial is cancelled</Text><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339170" lims:id="1339170"><Label>(i)</Label><Text>in the case of a drug, under</Text><Clause lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339171" lims:id="1339171"><Label>(A)</Label><Text>section C.03.319 or paragraph C.05.016(4)(b) or C.05.017(3)(b) of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>, or</Text></Clause><Clause lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339172" lims:id="1339172"><Label>(B)</Label><Text>paragraph 82(b) of the <XRefExternal reference-type="regulation" link="SOR-2003-196">Natural Health Products Regulations</XRefExternal>, and</Text></Clause></Subparagraph><Subparagraph lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339173" lims:id="1339173"><Label>(ii)</Label><Text>in the case of a device, under paragraph 85(2)(b) of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal>.</Text></Subparagraph></Paragraph></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339174" lims:id="1339174"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339175" lims:id="1339175">Partial suspensions or revocations</MarginalNote><Label>(4)</Label><Text>If the authorization referred to in paragraph (1)(b) or (3)(b) is only partially suspended or cancelled, the authorization to conduct the clinical trial is suspended or revoked to the same extent.</Text></Subsection></Section><Heading lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1339176" lims:id="1339176" level="1"><Label>PART 5</Label><TitleText>Transitional Provisions</TitleText></Heading><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339177" lims:id="1339177"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339178" lims:id="1339178">Definition of <DefinitionRef>Interim Order No. 2</DefinitionRef></MarginalNote><Label>42</Label><Text>In sections 43 to 52, <DefinedTermEn>Interim Order No. 2</DefinedTermEn> means the <XRefExternal reference-type="other">Interim Order No. 2 Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19</XRefExternal>, made by the Minister on May 3, 2021, and published in Part I of the <XRefExternal reference-type="other" link="gazette">Canada Gazette</XRefExternal> on May 22, 2021.</Text></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339179" lims:id="1339179"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339180" lims:id="1339180">Applications</MarginalNote><Label>43</Label><Text>An application for a COVID-19 medical device authorization or a COVID-19 drug authorization that was submitted to the Minister under Interim Order No. 2 before the day on which this section comes into force and in respect of which no decision has been made before that day is deemed to be an application for a COVID-19 medical device authorization or a COVID-19 drug authorization submitted under these Regulations.</Text></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339181" lims:id="1339181"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339182" lims:id="1339182">Authorizations</MarginalNote><Label>44</Label><Text>A COVID-19 medical device authorization or a COVID-19 drug authorization that was issued or reinstated by the Minister under Interim Order No. 2 before the day on which this section comes into force and that has not been revoked in whole before that day is deemed to be a COVID-19 medical device authorization or a COVID-19 drug authorization issued or reinstated under these Regulations.</Text></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339183" lims:id="1339183"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339184" lims:id="1339184">Approval — research ethics board</MarginalNote><Label>45</Label><Text>Any approval of a research ethics board that was obtained by a holder of a COVID-19 medical device authorization or a holder of a COVID-19 drug authorization under Interim Order No. 2 before the day on which this section comes into force is deemed to be an approval of the research ethics board obtained by the holder of a COVID-19 medical device authorization or the holder of a COVID-19 drug authorization under these Regulations.</Text></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339185" lims:id="1339185"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339186" lims:id="1339186">Terms and conditions</MarginalNote><Label>46</Label><Text>Any terms and conditions that were imposed on a COVID-19 medical device authorization or a COVID-19 drug authorization by the Minister under Interim Order No. 2 before the day on which this section comes into force are deemed to be terms and conditions imposed on the COVID-19 medical device authorization or the COVID-19 drug authorization under these Regulations.</Text></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339187" lims:id="1339187"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339188" lims:id="1339188">Amendment applications</MarginalNote><Label>47</Label><Text>An application to amend a COVID-19 medical device authorization or a COVID-19 drug authorization that was submitted to the Minister under Interim Order No. 2 before the day on which this section comes into force and in respect of which no decision has been made before that day is deemed to be an application to amend a COVID-19 medical device authorization or a COVID-19 drug authorization submitted under these Regulations.</Text></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339189" lims:id="1339189"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339190" lims:id="1339190">Amended authorization</MarginalNote><Label>48</Label><Text>A COVID-19 medical device authorization or a COVID-19 drug authorization that was amended by the Minister under Interim Order No. 2 before the day on which this section comes into force and that has not been revoked in whole before that day is deemed to be a COVID-19 medical device authorization or a COVID-19 drug authorization amended to the same extent under these Regulations.</Text></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339191" lims:id="1339191"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339192" lims:id="1339192">Suspension</MarginalNote><Label>49</Label><Text>A COVID-19 medical device authorization or a COVID-19 drug authorization that was suspended in whole or in part by the Minister under Interim Order No. 2 before the day on which this section comes into force and that has not been revoked in whole before that day is deemed to be a COVID-19 medical device authorization or a COVID-19 drug authorization suspended in whole or in part to the same extent under these Regulations.</Text></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339193" lims:id="1339193"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339194" lims:id="1339194">Request — additional information and material</MarginalNote><Label>50</Label><Text>A request for additional information or material, including samples, that was made by the Minister under Interim Order No. 2 before the day on which this section comes into force is deemed to be a request for additional information or material under these Regulations.</Text></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339195" lims:id="1339195"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339196" lims:id="1339196">Discontinuance</MarginalNote><Label>51</Label><Text>A notice of discontinuance provided to the Minister, or information in respect of discontinuance provided in writing to a qualified investigator, by the holder of a COVID-19 medical device authorization or a COVID-19 drug authorization under Interim Order No. 2 before the day on which this section comes into force is deemed to be a notice of discontinuance or information provided under these Regulations.</Text></Section><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339197" lims:id="1339197"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339198" lims:id="1339198">Revocation in part</MarginalNote><Label>52</Label><Text>A COVID-19 medical device authorization or a COVID-19 drug authorization that was revoked in part by the Minister under Interim Order No. 2 before the day on which this section comes into force and that has not been revoked in whole before that day is deemed to be a COVID-19 medical device authorization or a COVID-19 drug authorization revoked in part to the same extent under these Regulations.</Text></Section><Heading lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1339199" lims:id="1339199" level="1"><Label>PART 6</Label><TitleText>Consequential Amendments, Related Amendments and Coming into Force</TitleText></Heading><Heading lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1339200" lims:id="1339200" level="2"><TitleText>Consequential Amendments</TitleText></Heading><Heading lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1339201" lims:id="1339201" level="3"><TitleText><XRefExternal reference-type="regulation" link="SOR-2017-165">Certificate of Supplementary Protection Regulations</XRefExternal></TitleText></Heading><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339202" lims:id="1339202" target="SOR/2017-165" type="amending"><Label>53</Label><Text>[Amendments]</Text></Section><Heading lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1339204" lims:id="1339204" level="3"><TitleText><XRefExternal reference-type="regulation">Regulations Amending Certain Regulations Concerning Drugs and Medical Devices (Shortages)</XRefExternal></TitleText></Heading><Section lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-11" lims:fid="1339205" lims:id="1339205" target="SOR/2021-199" type="amending"><Label>54</Label><Text>[Amendments]</Text></Section><Heading lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1339207" lims:id="1339207" level="2"><TitleText>Related Amendments</TitleText></Heading><Heading lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1339208" lims:id="1339208" level="3"><TitleText><XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal></TitleText></Heading><Section lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-11" lims:fid="1339209" lims:id="1339209" target="C.R.C., c. 870" type="amending"><Label>55</Label><Text>[Amendments]</Text></Section><Heading lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1339211" lims:id="1339211" level="3"><TitleText><XRefExternal reference-type="regulation" link="SOR-2003-196">Natural Health Products Regulations</XRefExternal></TitleText></Heading><Section lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-11" lims:fid="1339212" lims:id="1339212" target="SOR/2003-196" type="amending"><Label>56</Label><Text>[Amendments]</Text></Section><Heading lims:inforce-start-date="2022-02-11" lims:enacted-date="2022-02-11" lims:fid="1339214" lims:id="1339214" level="2"><TitleText>Coming into Force</TitleText></Heading><Section lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:lastAmendedDate="2022-02-27" lims:fid="1339215" lims:id="1339743" type="CIF"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339744" lims:id="1339744">Registration</MarginalNote><Label><FootnoteRef idref="footnote_e">*</FootnoteRef>57</Label><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339745" lims:id="1339745" type="transitional"><Label>(1)</Label><Text>Subject to subsection (2), these Regulations come into force on the day on which they are registered.</Text></Subsection><Subsection lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339746" lims:id="1339746" type="transitional"><MarginalNote lims:inforce-start-date="2022-02-27" lims:enacted-date="2022-02-11" lims:fid="1339747" lims:id="1339747">Cessation of effect of interim order</MarginalNote><Label>(2)</Label><Text>Sections 1 to 53 come into force on the day following the day on which the <XRefExternal reference-type="other">Interim Order No. 2 Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19</XRefExternal>, made by the Minister on May 3, 2021, and published in the Part I of the <XRefExternal reference-type="other" link="gazette">Canada Gazette</XRefExternal> on May 22, 2021, ceases to have effect.</Text></Subsection><Footnote id="footnote_e" placement="section" status="editorial"><Label>*</Label><Text>[Note: Sections 1 to 53 in force February 27, 2022.]</Text></Footnote></Section></Body><RecentAmendments><Amendment><AmendmentCitation>SOR/2022-18</AmendmentCitation><AmendmentDate>2022-02-27</AmendmentDate></Amendment></RecentAmendments></Regulation>